<?xml version="1.0" encoding="UTF-8"?>
<ref id="B44-pharmaceuticals-13-00096">
 <label>44.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Toovey</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Prinssen</surname>
    <given-names>E.P.</given-names>
   </name>
   <name>
    <surname>Rayner</surname>
    <given-names>C.R.</given-names>
   </name>
   <name>
    <surname>Thakrar</surname>
    <given-names>B.T.</given-names>
   </name>
   <name>
    <surname>Dutkowski</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Koerner</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Chu</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Sirzen-Zelenskaya</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Britschgi</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Bansod</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: An updated review</article-title>
  <source>Adv. Ther.</source>
  <year>2012</year>
  <volume>29</volume>
  <fpage>826</fpage>
  <lpage>848</lpage>
  <pub-id pub-id-type="doi">10.1007/s12325-012-0050-8</pub-id>
  <?supplied-pmid 23054689?>
  <pub-id pub-id-type="pmid">23054689</pub-id>
 </element-citation>
</ref>
